Genocea Biosciences Inc logo

Genocea Biosciences Inc - Warrants - Class A (

(Warrants)
OTCPK:GGNNQ (USA)   Warrants - Class A (09/01/2023)
$ 0.00 0 (0%) 09:42 AM EST
At Loss
Volume:
20.00K
Avg Vol (2M):
-
Also Trade In:
Volume:
20.00K
At Loss

Business Description

Genocea Biosciences Inc logo
Genocea Biosciences Inc
NAICS : 325412 SIC : 2834

Share Class Description:

GGNNQ: Warrants - Class A (09/01/2023)
Description
Genocea Biosciences Inc is a US-based biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies to address diseases with significant unmet needs. Its product candidate includes GEN-003 which is an immunotherapy for the treatment of genital herpes as well as it owns a pre-clinical immuno-oncology program focused on personalized cancer vaccines. The company focuses on developing vaccines and immunotherapies for unmet needs through its AnTigen Lead Acquisition System, which is used to design vaccines and immunotherapies. Genocea operates its business through the single segment being Developing and Commercializing vaccines.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt 1.3
Equity-to-Asset 0.32
Debt-to-Equity 1.25
Debt-to-EBITDA -0.45
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -18.12
Distress
Grey
Safe
Beneish M-Score -3.33
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 1.35
Quick Ratio 1.35
Cash Ratio 1.12

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -75.1
Shareholder Yield % 5.61

Profitability Rank

Name Current Vs Industry Vs History
Operating Margin % -2901.31
Net Margin % -1946.15
ROE % -223.76
ROA % -57.93
ROIC % -241.51
ROC (Joel Greenblatt) % -267.75
ROCE % -74.22

GF Value Rank

Name Current Vs Industry Vs History
EV-to-EBIT 0.13
EV-to-EBITDA 0.13
EV-to-Revenue -2.43
EV-to-FCF 0.09
Earnings Yield (Greenblatt) % 769.23
FCF Yield % -855433.33